1 Small-Cap Biotech Stock Poised for a Breakout

Some prominent biotech companies tend to capture the majority of investors' and analysts' attention compared to their industry peers. aTyr Pharma (NASDAQ: LIFE), a small-cap, clinical-stage biotech, doesn't belong to that group.However, the drugmaker has performed well this year; its shares are up 40% year to date. What's more, aTyr Pharma could have even more upside in the (very) near future. Is the stock a good investment at this time? Let's find out.aTyr Pharma's shares have performed well this year, partly in anticipation of the release of data from an ongoing phase 3 study of its leading candidate, efzofitimod. The small-cap biotech company said it would announce results from this trial in mid-September, so that should be coming pretty soon.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool